The medical tech firm reported $28.6 million in Q4 FY2026 revenue and over 6,300 prescriptions for its ASSURE system.
Kestra Medical Technologies outlined a revenue target of $137 million for fiscal year 2027, aiming for gross margins above 70% in the coming years. The company closed FY2026 with $28.6 million in revenue for the fourth quarter, reflecting continued growth in its medical device segment.
Management highlighted over 6,300 prescriptions written for its ASSURE system during the period. The company’s focus on expanding margins aligns with its long-term profitability goals, though prior-year comparisons or consensus estimates were not disclosed.
No immediate market reaction was detailed in the earnings call summary.